Results 51 to 60 of about 451,745 (342)

Clinical use of HIV integrase inhibitors : a systematic review and meta-analysis [PDF]

, 2013
Background: Optimal regimen choice of antiretroviral therapy is essential to achieve long-term clinical success. Integrase inhibitors have swiftly been adopted as part of current antiretroviral regimens.
A Talbot, AJ Viera, Annemarie M. J. Wensing, AR Zolopa, Axel Fun, B Grinsztejn, B Taiwo, B Young, C Cohen, C Garrido, D McMahon, D Moher, DK Owens, DV Cordery, E DeJesus, E Martinez, E Vispo, EM Gardner, F Caby, F Canducci, F Smith, H Byakwaga, H Hatano, J Reynes, J van Lunzen, JJ Eron, JJ Eron Jr, JK Rockstroh, JL Lennox, JL Lennox, JM Gatell, JM Molina, JR Santos, L Van Wesenbeeck, L Wittkop, Linos Vandekerckhove, Luis Menéndez-Arias, M Harris, M Markowitz, M Markowitz, MA Thompson, MJ Buzon, MJ Kozal, Monique Nijhuis, N Mantel, Nele Brusselaers, O Goethals, PE Sax, Peter Messiaen, R Qaqish, R Relevo, RT Gandhi, RT Gandhi, RT Steigbigel, RT Steigbigel, S Gallien, S Nozza, V Dahl, W Towner, Y Yazdanpanah   +59 more
core   +10 more sources

Methoxyflavones from as HIV-1 Reverse Transcriptase Inhibitors

Natural Product Communications, 2017
Methoxyflavones are flavonoid widely distributed in plants and has been reported as potent antitumor agents and some of them have shown activity against HIV-1. In this work, two methoxyflavones isolated from Marcetia taxifolia were evaluated in vitro and
Joseph T Ortega, María Luisa Serrano, Alírica I Suárez, Jani Baptista, Flor H Pujol, Héctor R Rangel   +5 more
doaj   +1 more source

Hepatotoxicity of Contemporary Antiretroviral Drugs: A Review and Evaluation of Published Clinical Data

Cells, 2021
Contemporary antiretroviral agents afford enhanced potency and safety for patients living with HIV. Newer antiretroviral drugs are often better tolerated than those initially approved in the early stages of the HIV epidemic.
Ashley O. Otto, Christina G. Rivera, John D. Zeuli, Zelalem Temesgen   +3 more
doaj   +1 more source

Discovery of piperidine-substituted thiazolo[5,4-d]pyrimidine derivatives as potent and orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitors

Communications Chemistry, 2019
HIV-1 reverse transcriptase offers a key target for antiviral therapy. However, the rapid emergence of drug-resistant mutations in reverse transcriptase as well as the poor pharmacokinetic properties of HIV-1 non-nucleoside reverse transcriptase ...
Dongwei Kang, Tong Zhao, Zhao Wang, Da Feng, Heng Zhang, Boshi Huang, Gaochan Wu, Fenju Wei, Zhongxia Zhou, Lanlan Jing, Xiaofang Zuo, Ye Tian, Vasanthanathan Poongavanam, J. Kongsted, E. De Clercq, C. Pannecouque, P. Zhan, Xinyong Liu   +17 more
semanticscholar   +1 more source

Lipometabolic side-effects of three ritonavir-boosted double protease inhibitor regimens without reverse transcriptase inhibitors [PDF]

, 2008
Poster presentation: Purpose of the study To compare the lipometabolic profiles of three double-boosted protease inhibitor (PI) regimens at standard dose, containing saquinavir and ritonavir in combination with lopinavir (LOPSAQ), atazanavir (ATSAQ) or ...
Bickel, Markus, Hentig, Nils von, Khaykin, Pavel, Knecht, Gaby, Lennemann, Tessa, Lutz, Thomas, Staszewski, Schlomo, Stephan, Christoph, Wendig, Annette   +8 more
core   +1 more source

Twenty-six years of HIV science: an overview of anti-HIV drugs metabolism

Brazilian Journal of Pharmaceutical Sciences, 2011
From the identification of HIV as the agent causing AIDS, to the development of effective antiretroviral drugs, the scientific achievements in HIV research over the past twenty-six years have been formidable.
Carolina Horta Andrade, Lenis Medeiros de Freitas, Valéria de Oliveira   +2 more
doaj   +1 more source

Reverse transcriptase inhibition: a way to defeat HIV

HIV & AIDS Review. International Journal of HIV-Related Problems, 2022
Human immunodeficiency virus (HIV) induces disease in humans that is known as AIDS (acquired immunodeficiency syndrome). First AIDS cases were registered in 1981, and later, types of HIV infection, such as HIV-1 and HIV-2 were identified.
Vikas Kumar, Harish Joshi, I. Pandey
doaj   +1 more source

Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: Prevalence and metabolic consequences [PDF]

, 2010
Lipoatrophy and metabolic complications of treatment of human immunodeficiency virus (HIV) infection may share common associations with adipose tissue pathology and inflammation.
Hammond, E.L., McKinnon, E., Nolan, D.
core   +2 more sources

The “Connection” Between HIV Drug Resistance and RNase H

Viruses, 2010
Currently, nucleoside reverse transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) are two classes of antiretroviral agents that are approved for treatment of HIV-1 infection. Since both NRTIs and NNRTIs target the
Krista A. Delviks-Frankenberry, Vinay K. Pathak, Galina N. Nikolenko   +2 more
doaj   +1 more source

Drug resistance and viral tropism in HIV-1 subtype C-infected patients in KwaZulu-Natal, South Africa: implications for future treatment options [PDF]

, 2011
Article approval pendingDrug resistance poses a significant challenge for the successful application of highly active antiretroviral therapy (HAART) globally. Furthermore, emergence of HIV-1 isolates that preferentially use CXCR4 as a coreceptor for cell
Ashika Singh, Bjorndal, Brenner, Briggs, Briz, Cann, Cecilia, Cilliers, Coakley, Coetzer, Connor, Cozzi-Lepri, Daniel R. Kuritzkes, Elizabeth D. Anton, Fouchier, Fouchier, Furtado, Henry Sunpath, Hosseinipour, Hunt, Irlbeck, Jacqueline D. Reeves, Johnston, Kantor, Keshni Hiramen, Kuiken, Loemba, Low, Marconi, Nagavelli Padayachi, Ndungu, Novitsky, Reeves, Richard Murphy, Rizzuto, Scarlatti, Singh, Tamura, Taryn N. Green, Taylor, Thumbi Ndung'u, Tobin, Trinh, Tscherning, Wallis, Westby, Whitcomb, Wu, Yolanda Lie   +48 more
core   +2 more sources